HomeCompareOCLDY vs JNJ

OCLDY vs JNJ: Dividend Comparison 2026

OCLDY yields 3.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OCLDY wins by $6.4K in total portfolio value
10 years
OCLDY
OCLDY
● Live price
3.00%
Share price
$12.66
Annual div
$0.38
5Y div CAGR
21.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$36.7K
Annual income
$3,542.78
Full OCLDY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — OCLDY vs JNJ

📍 OCLDY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOCLDYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OCLDY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OCLDY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OCLDY
Annual income on $10K today (after 15% tax)
$255.13/yr
After 10yr DRIP, annual income (after tax)
$3,011.36/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $974.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OCLDY + JNJ for your $10,000?

OCLDY: 50%JNJ: 50%
100% JNJ50/50100% OCLDY
Portfolio after 10yr
$33.5K
Annual income
$4,116.09/yr
Blended yield
12.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

OCLDY
No analyst data
Altman Z
3.2
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OCLDY buys
0
JNJ buys
0
No recent congressional trades found for OCLDY or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOCLDYJNJ
Forward yield3.00%2.13%
Annual dividend / share$0.38$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR21.5%28%
Portfolio after 10y$36.7K$30.3K
Annual income after 10y$3,542.78$4,689.40
Total dividends collected$14.1K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OCLDY vs JNJ ($10,000, DRIP)

YearOCLDY PortfolioOCLDY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,065$364.69$10,592$272.30+$473.00OCLDY
2$12,297$458.20$11,289$357.73+$1.0KOCLDY
3$13,737$578.26$12,123$472.89+$1.6KOCLDY
4$15,432$733.47$13,141$629.86+$2.3KOCLDY
5$17,447$935.63$14,408$846.81+$3.0KOCLDY
6$19,870$1,201.21$16,021$1,151.60+$3.8KOCLDY
7$22,814$1,553.38$18,122$1,588.22+$4.7KOCLDY
8$26,436$2,025.25$20,930$2,228.20+$5.5KOCLDY
9$30,952$2,664.82$24,792$3,191.91+$6.2KOCLDY
10$36,661$3,542.78$30,274$4,689.40+$6.4KOCLDY

OCLDY vs JNJ: Complete Analysis 2026

OCLDYStock

Orica Limited manufactures and sells commercial explosives and blasting systems in Australia, the United States, and internationally. The company provides 4D bulk explosives systems, packaged explosives, initiating systems, boosters, and seismic systems; and data, reporting, analytics, blasting, contracted, and supplementary services. It also offers automation solutions, including Avatel, a machine equipped with underground development charging system; and secondary breakage and hang up blasting, a tele-remote blasting solution. In addition, the company provides mining chemical products, such as cyanide sparges, emulsifiers, and sodium cyanide, as well as PRO services; digitally enabled benchmarks and insights at various stages of the blasting process; nitrogen fertilizers, which include urea ammonium nitrate and ammonia; and environmental monitoring and consultancy services. Further, it offers chemical and mechanical earth control products, adhesives, and ground support equipment comprising steel bolts and plates, glass fiber reinforced polymer bolts, injectable chemicals and foams, mesh, resin capsules, cementitious grouts and coatings, pumps, soil anchoring systems, ballast bonding polymers, and accessories, as well as engineering services. Additionally, the company provides resources to explore the use of chemical energy in blasting, blasting fundamentals, and properties of explosives and blast design principles; and geotechnical deformation and convergence monitoring solutions. It serves surface coal, surface metal, iron ore, quarrying, underground mining and construction, construction, civil infrastructure, oil and gas, and agriculture markets. The company was founded in 1874 and is headquartered in East Melbourne, Australia.

Full OCLDY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this OCLDY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OCLDY vs SCHDOCLDY vs JEPIOCLDY vs OOCLDY vs KOOCLDY vs MAINOCLDY vs ABBVOCLDY vs MRKOCLDY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.